Lixte Forum: Community User: DeRitter

Könnte mal steigen

Willkommen im Klub 🤞🏻

Mal sehen ob was kommt bezüglich Krebs

Auch drin

Schauen wir wo die Reise hingeht 💪

Wir heben ab

LIXT PR "EAST SETAUKET, NY, March 17, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, will participate in the virtual Benzinga Biotech Small Cap Conference being held March 24-25, 2021. Lixte Founder and Chief Executive Officer John S. Kovach, M.D., will present on Wednesday, March 24 at 10:55 a.m. ET in Track 1. Investors may register for the conference at the event website. During the corporate presentation and in one-on-one investor meetings, Dr. Kovach will discuss Lixte's product pipeline of ongoing studies and planned trials of its lead clinical candidate LB-100, a unique first-in-class anti-cancer agent with no competitors known to Lixte currently in the clinic. Dr. Kovach commented, "More than 40 preclinical studies with leading medical centers indicated that LB-100 enhances standard therapies for many cancers. We now have a number of exciting clinical investigations underway for LB-100, including three clinical trials and one pharmacology study. Our initial cancer targets are myelodysplastic syndrome, soft tissue sarcomas, small cell lung cancer, and glioblastoma.""

Pump and Dump 😂👍

👍👍

🤗

To be presented - Anti-Cancer Therapy Enhancer LB-100 at the Virtual 33rd Annual ROTH Capital Conference LB-100 is Currently in Clinical Studies for Four Cancer Targets: ◦ Phase 1b/2 for Myelodysplastic (MDS) Syndromes ◦ Phase 1b/2 for Advanced Soft Tissue Sarcoma ◦ Phase 0 (Pharmacodynamics) for Glioblastoma Multiforme ◦ Phase 1b for Small Cell Lung Cancer ◦ Pre-clinical for Angelman Syndrome

👋

🧐🧐🧐

🐥🐥🐥

😉

👋😁, woher die News